Blue Earth Diagnostics Limited Sustainability Profile
Blue Earth Diagnostics Limited, a leading innovator in the field of molecular imaging, is headquartered in Great Britain. Founded in 2014, the company has rapidly established itself as a key player in the development of diagnostic imaging agents, particularly for prostate cancer. With a focus on PET (positron emission tomography) imaging, Blue Earth Diagnostics offers unique radiopharmaceuticals that enhance the detection and management of cancer. Their flagship product, Axumin, is notable for its ability to detect prostate cancer recurrence with high specificity and sensitivity. The company has achieved significant milestones, including regulatory approvals in various regions, solidifying its position in the global market. Blue Earth Diagnostics continues to advance the field of oncology diagnostics, contributing to improved patient outcomes through innovative imaging solutions.
DitchCarbon Score
How does Blue Earth Diagnostics Limited's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Blue Earth Diagnostics Limited's score of 23 is lower than 68% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Blue Earth Diagnostics Limited, headquartered in Great Britain, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of Bracco S.p.A., which may influence its climate commitments and reporting practices. As of now, there are no documented reduction targets or climate pledges from Blue Earth Diagnostics Limited. The lack of specific emissions data and reduction initiatives suggests that the company may still be in the early stages of developing a comprehensive climate strategy. Given its affiliation with Bracco S.p.A., it is possible that emissions data and climate commitments could be inherited or influenced by the parent company's sustainability initiatives. However, without explicit data or targets from either Blue Earth Diagnostics Limited or Bracco S.p.A., it is challenging to provide a detailed overview of their carbon footprint or climate commitments. In summary, Blue Earth Diagnostics Limited currently lacks specific emissions data and reduction targets, reflecting a potential area for future development in their environmental strategy.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 49,469,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 41,475,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | - | - | - |
How Carbon Intensive is Blue Earth Diagnostics Limited's Industry?
How Carbon Intensive is Blue Earth Diagnostics Limited's Location?
Blue Earth Diagnostics Limited's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Blue Earth Diagnostics Limited has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
